TrialScope EXTRA Keynotes Address Data Ownership, Health Communication

As regulatory expectations evolve, clinical trial sponsors face growing pressure to manage protocol transparency, data governance, and disclosure compliance. Discussions at TrialScope EXTRA 2026 highlighted emerging challenges around data ownership, cross-border data access restrictions, AI-driven transparency risks, and the increasing complexity of federal, state, and global regulations. Expert keynote speakers explored how protocol design, amendment management, and registration practices directly influence compliance obligations, public trust, and patient access to trials.

The event sessions also examined the role of AI in automating protocol impact assessments, streamlining ClinicalTrials.gov compliance, and reducing transparency risk. From evolving disclosure requirements to questions surrounding data protection and intellectual property, the event underscored the need for proactive regulatory strategies that safeguard data while ensuring accurate, accessible, and compliant trial information throughout the development lifecycle.